Credit Suisse’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $151M | Sell |
280,010
-22,216
| -7% | -$12.1M | 0.14% | 125 |
|
|
2023
Q4 | $168M | Buy |
302,226
+17,282
| +6% | +$8.11M | 0.16% | 107 |
|
|
2023
Q3 | $125M | Sell |
284,944
-9,869
| -3% | -$4.92M | 0.13% | 150 |
|
|
2023
Q2 | $148M | Sell |
294,813
-7,100
| -2% | -$3.4M | 0.15% | 123 |
|
|
2023
Q1 | $151M | Sell |
301,913
-41,563
| -12% | -$19.9M | 0.15% | 130 |
|
|
2022
Q4 | $140M | Buy |
343,476
+218
| +0.1% | +$84.6K | 0.15% | 138 |
|
|
2022
Q3 | $112M | Sell |
343,258
-19,124
| -5% | -$7.03M | 0.12% | 166 |
|
|
2022
Q2 | $127M | Buy |
362,382
+23,470
| +7% | +$9.57M | 0.13% | 157 |
|
|
2022
Q1 | $185M | Buy |
338,912
+3,996
| +1% | +$2.1M | 0.16% | 127 |
|
|
2021
Q4 | $221M | Sell |
334,916
-5,841
| -2% | -$3.67M | 0.12% | 161 |
|
|
2021
Q3 | $212M | Sell |
340,757
-11,696
| -3% | -$7.86M | 0.12% | 159 |
|
|
2021
Q2 | $223M | Sell |
352,453
-11,410
| -3% | -$6.3M | 0.12% | 173 |
|
|
2021
Q1 | $178M | Buy |
363,863
+35,937
| +11% | +$18M | 0.09% | 235 |
|
|
2020
Q4 | $164M | Sell |
327,926
-142,472
| -30% | -$63.7M | 0.08% | 261 |
|
|
2020
Q3 | $185M | Sell |
470,398
-97,677
| -17% | -$36.1M | 0.11% | 184 |
|
|
2020
Q2 | $188M | Buy |
568,075
+3,606
| +0.6% | +$1.04M | 0.13% | 145 |
|
|
2020
Q1 | $137M | Sell |
564,469
-25,726
| -4% | -$6.71M | 0.12% | 147 |
|
|
2019
Q4 | $154M | Buy |
590,195
+113,036
| +24% | +$29.8M | 0.11% | 172 |
|
|
2019
Q3 | $130M | Sell |
477,159
-47,051
| -9% | -$13.1M | 0.11% | 171 |
|
|
2019
Q2 | $144M | Sell |
524,210
-112,435
| -18% | -$27.7M | 0.13% | 142 |
|
|
2019
Q1 | $142M | Buy |
636,645
+118,266
| +23% | +$24.4M | 0.13% | 138 |
|
|
2018
Q4 | $96.4M | Buy |
518,379
+41,474
| +9% | +$8.5M | 0.1% | 190 |
|
|
2018
Q3 | $119M | Buy |
476,905
+26,776
| +6% | +$6.5M | 0.11% | 172 |
|
|
2018
Q2 | $98.1M | Sell |
450,129
-132,741
| -23% | -$27.4M | 0.1% | 190 |
|
|
2018
Q1 | $112M | Buy |
582,870
+64,532
| +12% | +$11.9M | 0.1% | 188 |
|
|
2017
Q4 | $81.1M | Buy |
518,338
+17,595
| +4% | +$2.77M | 0.07% | 277 |
|
|
2017
Q3 | $77.9M | Buy |
500,743
+78,173
| +18% | +$12.4M | 0.08% | 278 |
|
|
2017
Q2 | $68.2M | Buy |
422,570
+22,705
| +6% | +$3.69M | 0.07% | 300 |
|
|
2017
Q1 | $61.8M | Buy |
399,865
+96,688
| +32% | +$13.3M | 0.06% | 361 |
|
|
2016
Q4 | $35.6M | Sell |
303,177
-140,881
| -32% | -$16.1M | 0.04% | 550 |
|
|
2016
Q3 | $50.1M | Sell |
444,058
-132,409
| -23% | -$14M | 0.05% | 424 |
|
|
2016
Q2 | $53.5M | Buy |
576,467
+121,450
| +27% | +$10.4M | 0.06% | 345 |
|
|
2016
Q1 | $35.6M | Buy |
455,017
+35,010
| +8% | +$2.52M | 0.04% | 478 |
|
|
2015
Q4 | $30.6M | Sell |
420,007
-16,094
| -4% | -$1.15M | 0.04% | 576 |
|
|
2015
Q3 | $32.4M | Buy |
436,101
+120,941
| +38% | +$8.66M | 0.04% | 531 |
|
|
2015
Q2 | $20.2M | Buy |
315,160
+52,046
| +20% | +$3.6M | 0.02% | 831 |
|
|
2015
Q1 | $20.3M | Buy |
263,114
+7,754
| +3% | +$603K | 0.02% | 809 |
|
|
2014
Q4 | $18.9M | Sell |
255,360
-48,290
| -16% | -$3.39M | 0.02% | 917 |
|
|
2014
Q3 | $17.9M | Buy |
303,650
+68,962
| +29% | +$4.36M | 0.01% | 968 |
|
|
2014
Q2 | $15.7M | Buy |
234,688
+11,578
| +5% | +$736K | 0.01% | 1087 |
|
|
2014
Q1 | $13.5M | Sell |
223,110
-77,090
| -26% | -$4.59M | 0.01% | 1051 |
|
|
2013
Q4 | $16M | Buy |
300,200
+60,172
| +25% | +$3.17M | 0.01% | 954 |
|
|
2013
Q3 | $12M | Sell |
240,028
-18,066
| -7% | -$868K | 0.01% | 1019 |
|
|
2013
Q2 | $11.6M | Buy |
+258,094
| New | +$11.3M | 0.01% | 1046 |
|
Other funds holding IDXX
Credit Suisse's IDXX Position: Q1 2024 in Review
Credit Suisse reduced its Idexx Laboratories (IDXX) stake by 7.4% in Q1 2024, selling an estimated $12.1M and leaving 280,010 shares worth $151M. The position accounts for 0.14% of the portfolio, ranked #125.
Credit Suisse first reported a position in IDXX in Q2 2013 and has held it in 44 quarters since. The position peaked at $223M in Q2 2021. 1,148 funds tracked by Wall St. Rank hold IDXX as of Q1 2024.
- Credit Suisse held 280,010 shares of Idexx Laboratories worth $151M as of Q1 2024.
- Credit Suisse sold 22,216 Idexx Laboratories shares in Q1 2024, an estimated $12.1M.
- Idexx Laboratories made up 0.14% of Credit Suisse's portfolio in Q1 2024, its #125 holding.
- Credit Suisse first reported a position in Idexx Laboratories in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Idexx Laboratories position peaked at $223M in Q2 2021.
- 1,148 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.